Tonix announces positive FDA meeting minutes for Lyme disease antibody TNX-4800

Tonix Pharmaceuticals announced positive feedback for the design of an adaptive Phase 2 Lyme disease study of TNX-4800, with plans to begin the trial in early 2027. The long-acting monoclonal antibody offers a potential preventative alternative to vaccines that requires fewer doses.